You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameMethyclothiazide
Accession NumberDB00232  (APRD01104)
TypeSmall Molecule
GroupsApproved
DescriptionA thiazide diuretic with properties similar to those of hydrochlorothiazide. (From Martindale, The Extra Pharmacopoeia, 30th ed, p825)
Structure
Thumb
Synonyms
Enduron
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Duretic 5mgtablet5 mgoralAbbott Laboratories, Limited1960-12-311999-08-09Canada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Methyclothiazidetablet5 mg/1oralMylan Pharmaceuticals Inc.1982-08-17Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
AquatensenNot Available
DureticNot Available
EnduronNot Available
Brand mixturesNot Available
SaltsNot Available
Categories
UNIIL3H46UAC61
CAS number135-07-9
WeightAverage: 360.237
Monoisotopic: 358.956802649
Chemical FormulaC9H11Cl2N3O4S2
InChI KeyInChIKey=CESYKOGBSMNBPD-UHFFFAOYSA-N
InChI
InChI=1S/C9H11Cl2N3O4S2/c1-14-9(4-10)13-6-2-5(11)7(19(12,15)16)3-8(6)20(14,17)18/h2-3,9,13H,4H2,1H3,(H2,12,15,16)
IUPAC Name
6-chloro-3-(chloromethyl)-2-methyl-1,1-dioxo-3,4-dihydro-2H-1λ⁶,2,4-benzothiadiazine-7-sulfonamide
SMILES
CN1C(CCl)NC2=CC(Cl)=C(C=C2S1(=O)=O)S(N)(=O)=O
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as benzothiadiazines. These are organic compounds containing a benzene fused to a thiadiazine ring (a six-member ring with two nitrogen atoms and a sulfur atom).
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassThiadiazines
Sub ClassBenzothiadiazines
Direct ParentBenzothiadiazines
Alternative Parents
Substituents
  • Benzothiadiazine
  • Benzenesulfonamide
  • Secondary aliphatic/aromatic amine
  • Chlorobenzene
  • Benzenoid
  • Aryl halide
  • Aryl chloride
  • Aminosulfonyl compound
  • Sulfonyl
  • Sulfonic acid derivative
  • Sulfonamide
  • Azacycle
  • Secondary amine
  • Hydrocarbon derivative
  • Organosulfur compound
  • Organonitrogen compound
  • Organochloride
  • Organohalogen compound
  • Amine
  • Alkyl halide
  • Alkyl chloride
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External DescriptorsNot Available
Pharmacology
IndicationFor use in the management of hypertension either as the sole therapeutic agent or to enhance the effect of other antihypertensive drugs in the more severe forms of hypertension. Also used as adjunctive therapy in edema associated with congestive heart failure, hepatic cirrhosis, and corticosteroid and estrogen therapy.
PharmacodynamicsMethyclothiazide, a diuretic-antihypertensive agent, is a member of the benzothiadiazine (thiazide) class of drugs. Methyclothiazide has a per mg natriuretic activity approximately 100 times that of the prototype thiazide, chlorothiazide. At maximal therapeutic dosages, all thiazides are approximately equal in their diuretic/natriuretic effects. Like other benzothiadiazines, methyclothiazide also has antihypertensive properties, and may be used for this purpose either alone or to enhance the antihypertensive action of other drugs.
Mechanism of actionMethyclothiazide appears to block the active reabsorption of chloride and possibly sodium in the ascending loop of Henle, altering electrolyte transfer in the proximal tubule. This results in excretion of sodium, chloride, and water and, hence, diuresis. As a diuretic, methyclothiazide inhibits active chloride reabsorption at the early distal tubule via the Na-Cl cotransporter, resulting in an increase in the excretion of sodium, chloride, and water. Thiazides like methyclothiazide also inhibit sodium ion transport across the renal tubular epithelium through binding to the thiazide sensitive sodium-chloride transporter. This results in an increase in potassium excretion via the sodium-potassium exchange mechanism. The antihypertensive mechanism of methyclothiazide is less well understood although it may be mediated through its action on carbonic anhydrases in the smooth muscle or through its action on the large-conductance calcium-activated potassium (KCa) channel, also found in the smooth muscle.
Related Articles
AbsorptionRapidly absorbed following oral administration.
Volume of distributionNot Available
Protein bindingNot Available
MetabolismNot Available
Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicityAcute oral toxicity (LD50): >4000 mg/kg [Rat]. Symptoms of overdosage include electrolyte imbalance and signs of potassium deficiency such as confusion, dizziness, muscular weakness, and gastrointestinal disturbances.
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Methyclothiazide Action PathwayDrug actionSMP00081
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9834
Blood Brain Barrier-0.6866
Caco-2 permeable-0.6992
P-glycoprotein substrateSubstrate0.5317
P-glycoprotein inhibitor INon-inhibitor0.8518
P-glycoprotein inhibitor IINon-inhibitor0.8888
Renal organic cation transporterNon-inhibitor0.8177
CYP450 2C9 substrateNon-substrate0.631
CYP450 2D6 substrateNon-substrate0.8261
CYP450 3A4 substrateNon-substrate0.532
CYP450 1A2 substrateNon-inhibitor0.6883
CYP450 2C9 inhibitorNon-inhibitor0.6493
CYP450 2D6 inhibitorNon-inhibitor0.858
CYP450 2C19 inhibitorNon-inhibitor0.808
CYP450 3A4 inhibitorInhibitor0.5094
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.7345
Ames testNon AMES toxic0.8905
CarcinogenicityNon-carcinogens0.82
BiodegradationNot ready biodegradable0.9971
Rat acute toxicity1.9853 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9384
hERG inhibition (predictor II)Non-inhibitor0.9318
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Medpointe pharmaceuticals medpointe healthcare inc
  • Abbott laboratories pharmaceutical products div
  • Ivax pharmaceuticals inc
  • Mylan pharmaceuticals inc
  • Par pharmaceutical inc
  • Sandoz inc
  • Usl pharma inc
  • Watson laboratories inc
Packagers
Dosage forms
FormRouteStrength
Tabletoral5 mg
Tabletoral5 mg/1
Prices
Unit descriptionCostUnit
Methyclothiazide powder11.32USD g
Enduron 5 mg tablet0.77USD tablet
Methyclothiazide 5 mg tablet0.77USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point225 °CPhysProp
water solubility11.2 mg/LNot Available
logP1.42HANSCH,C ET AL. (1995)
pKa9.4MERCK INDEX (2001)
Predicted Properties
PropertyValueSource
Water Solubility0.824 mg/mLALOGPS
logP0.93ALOGPS
logP0.53ChemAxon
logS-2.6ALOGPS
pKa (Strongest Acidic)9.29ChemAxon
pKa (Strongest Basic)-3.4ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area109.57 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity77.28 m3·mol-1ChemAxon
Polarizability31.65 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis ReferenceNot Available
General ReferencesNot Available
External Links
ATC CodesC03AA08C03AB08
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSDownload (74.8 KB)
Interactions
Drug Interactions
Drug
4-Androstenedione4-Androstenedione may increase the hypokalemic activities of Methyclothiazide.
AcarboseThe therapeutic efficacy of Acarbose can be decreased when used in combination with Methyclothiazide.
AcebutololThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Acebutolol.
AceclofenacThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Aceclofenac.
AcetazolamideThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Acetazolamide.
AcetohexamideThe therapeutic efficacy of Acetohexamide can be decreased when used in combination with Methyclothiazide.
AcetyldigitoxinThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Acetyldigitoxin.
Acetylsalicylic acidThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Acetylsalicylic acid.
AclidiniumThe serum concentration of Methyclothiazide can be increased when it is combined with Aclidinium.
AdapaleneThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Adapalene.
AicarThe therapeutic efficacy of Aicar can be decreased when used in combination with Methyclothiazide.
AlclometasoneAlclometasone may increase the hypokalemic activities of Methyclothiazide.
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Methyclothiazide.
AldosteroneAldosterone may increase the hypokalemic activities of Methyclothiazide.
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Methyclothiazide.
AliskirenThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Aliskiren.
AllopurinolThe risk of a hypersensitivity reaction to Allopurinol is increased when it is combined with Methyclothiazide.
AlogliptinThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Methyclothiazide.
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Methyclothiazide.
AmcinonideAmcinonide may increase the hypokalemic activities of Methyclothiazide.
AmilorideThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Amiloride.
AmlodipineThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Amlodipine.
AmobarbitalAmobarbital may increase the orthostatic hypotensive activities of Methyclothiazide.
AmoxapineAmoxapine may increase the hyponatremic activities of Methyclothiazide.
Amyl NitriteThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Amyl Nitrite.
Anisotropine MethylbromideThe serum concentration of Methyclothiazide can be increased when it is combined with Anisotropine Methylbromide.
AntipyrineThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Antipyrine.
ApraclonidineThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Apraclonidine.
ApremilastThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Apremilast.
ArbutamineArbutamine may increase the hypokalemic activities of Methyclothiazide.
ArformoterolArformoterol may increase the hypokalemic activities of Methyclothiazide.
AripiprazoleAripiprazole may increase the hypotensive activities of Methyclothiazide.
AtenololThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Atenolol.
Atracurium besylateThe serum concentration of Methyclothiazide can be increased when it is combined with Atracurium besylate.
AtropineThe serum concentration of Methyclothiazide can be increased when it is combined with Atropine.
AzapropazoneThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Azapropazone.
AzelastineThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Azelastine.
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Azilsartan medoxomil.
BalsalazideThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Balsalazide.
BambuterolBambuterol may increase the hypokalemic activities of Methyclothiazide.
BarbitalBarbital may increase the orthostatic hypotensive activities of Methyclothiazide.
Beclomethasone dipropionateBeclomethasone dipropionate may increase the hypokalemic activities of Methyclothiazide.
BenactyzineThe serum concentration of Methyclothiazide can be increased when it is combined with Benactyzine.
BenazeprilMethyclothiazide may increase the hypotensive activities of Benazepril.
BenazeprilThe risk or severity of adverse effects can be increased when Benazepril is combined with Methyclothiazide.
BendroflumethiazideThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Bendroflumethiazide.
BenoxaprofenThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Benoxaprofen.
BenzatropineThe serum concentration of Methyclothiazide can be increased when it is combined with Benzatropine.
BetamethasoneBetamethasone may increase the hypokalemic activities of Methyclothiazide.
BetaxololThe risk or severity of adverse effects can be increased when Betaxolol is combined with Methyclothiazide.
BezitramideThe risk or severity of adverse effects can be increased when Bezitramide is combined with Methyclothiazide.
BiperidenThe serum concentration of Methyclothiazide can be increased when it is combined with Biperiden.
BisoprololThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Bisoprolol.
BretyliumThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Bretylium.
BrimonidineThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Brimonidine.
BromfenacThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Bromfenac.
BudesonideBudesonide may increase the hypokalemic activities of Methyclothiazide.
BuforminThe therapeutic efficacy of Buformin can be decreased when used in combination with Methyclothiazide.
BumetanideThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Bumetanide.
BuprenorphineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Methyclothiazide.
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Methyclothiazide.
CanagliflozinThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Methyclothiazide.
CanagliflozinThe risk or severity of adverse effects can be increased when Canagliflozin is combined with Methyclothiazide.
CandesartanThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Candesartan.
CandoxatrilMethyclothiazide may increase the hypotensive activities of Candoxatril.
CaptoprilMethyclothiazide may increase the hypotensive activities of Captopril.
CaptoprilThe risk or severity of adverse effects can be increased when Captopril is combined with Methyclothiazide.
CarbamazepineThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Carbamazepine.
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Methyclothiazide.
CarprofenThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Carprofen.
CarteololThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Carteolol.
CarvedilolThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Carvedilol.
CastanospermineThe therapeutic efficacy of Castanospermine can be decreased when used in combination with Methyclothiazide.
CelecoxibThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Celecoxib.
CeliprololCeliprolol may increase the hypokalemic activities of Methyclothiazide.
ChloroquineThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Chloroquine.
ChlorothiazideThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Chlorothiazide.
ChlorphenoxamineThe serum concentration of Methyclothiazide can be increased when it is combined with Chlorphenoxamine.
ChlorpropamideThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Methyclothiazide.
ChlorthalidoneThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Chlorthalidone.
CholestyramineCholestyramine can cause a decrease in the absorption of Methyclothiazide resulting in a reduced serum concentration and potentially a decrease in efficacy.
CiclesonideCiclesonide may increase the hypokalemic activities of Methyclothiazide.
CiglitazoneThe therapeutic efficacy of Ciglitazone can be decreased when used in combination with Methyclothiazide.
CilazaprilMethyclothiazide may increase the hypotensive activities of Cilazapril.
CilazaprilThe risk or severity of adverse effects can be increased when Cilazapril is combined with Methyclothiazide.
CitalopramCitalopram may increase the hyponatremic activities of Methyclothiazide.
ClenbuterolClenbuterol may increase the hypokalemic activities of Methyclothiazide.
ClevidipineThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Clevidipine.
Clobetasol propionateClobetasol propionate may increase the hypokalemic activities of Methyclothiazide.
ClocortoloneClocortolone may increase the hypokalemic activities of Methyclothiazide.
ClomipramineClomipramine may increase the hyponatremic activities of Methyclothiazide.
ClonidineThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Clonidine.
ClonixinThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Clonixin.
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Methyclothiazide.
ColesevelamColesevelam can cause a decrease in the absorption of Methyclothiazide resulting in a reduced serum concentration and potentially a decrease in efficacy.
ColestipolColestipol can cause a decrease in the absorption of Methyclothiazide resulting in a reduced serum concentration and potentially a decrease in efficacy.
Cortisone acetateCortisone acetate may increase the hypokalemic activities of Methyclothiazide.
CyclopentolateThe serum concentration of Methyclothiazide can be increased when it is combined with Cyclopentolate.
CyclophosphamideThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Cyclophosphamide.
D-LimoneneThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with D-Limonene.
DapagliflozinThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Dapagliflozin.
DapoxetineDapoxetine may increase the hyponatremic activities of Methyclothiazide.
DarifenacinThe serum concentration of Methyclothiazide can be increased when it is combined with Darifenacin.
DehydroepiandrosteroneDehydroepiandrosterone may increase the hypokalemic activities of Methyclothiazide.
dehydroepiandrosterone sulfatedehydroepiandrosterone sulfate may increase the hypokalemic activities of Methyclothiazide.
DeslanosideThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Deslanoside.
DesloratadineThe serum concentration of Methyclothiazide can be increased when it is combined with Desloratadine.
DesoximetasoneDesoximetasone may increase the hypokalemic activities of Methyclothiazide.
Desoxycorticosterone acetateDesoxycorticosterone acetate may increase the hypokalemic activities of Methyclothiazide.
DexamethasoneDexamethasone may increase the hypokalemic activities of Methyclothiazide.
Dexamethasone isonicotinateDexamethasone isonicotinate may increase the hypokalemic activities of Methyclothiazide.
DexetimideThe serum concentration of Methyclothiazide can be increased when it is combined with Dexetimide.
DexketoprofenThe risk or severity of adverse effects can be increased when Dexketoprofen is combined with Methyclothiazide.
DexmedetomidineThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Dexmedetomidine.
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Methyclothiazide.
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Methyclothiazide.
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Methyclothiazide.
DiazoxideThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Diazoxide.
DiclofenacThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Diclofenac.
DiclofenamideThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Diclofenamide.
DicyclomineThe serum concentration of Methyclothiazide can be increased when it is combined with Dicyclomine.
DiflorasoneDiflorasone may increase the hypokalemic activities of Methyclothiazide.
DiflunisalThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Diflunisal.
DifluocortoloneDifluocortolone may increase the hypokalemic activities of Methyclothiazide.
DifluprednateDifluprednate may increase the hypokalemic activities of Methyclothiazide.
DigitoxinThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Digitoxin.
DigoxinThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Digoxin.
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Methyclothiazide.
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Methyclothiazide.
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Methyclothiazide.
DiltiazemThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Diltiazem.
DinutuximabThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Dinutuximab.
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Methyclothiazide.
DipivefrinDipivefrin may increase the hypokalemic activities of Methyclothiazide.
DipyridamoleThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Dipyridamole.
DobutamineDobutamine may increase the hypokalemic activities of Methyclothiazide.
DofetilideMethyclothiazide may increase the QTc-prolonging activities of Dofetilide.
DoxazosinThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Doxazosin.
DPDPEThe risk or severity of adverse effects can be increased when DPDPE is combined with Methyclothiazide.
DroxicamThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Droxicam.
DroxidopaDroxidopa may increase the hypokalemic activities of Methyclothiazide.
DulaglutideThe therapeutic efficacy of Dulaglutide can be decreased when used in combination with Methyclothiazide.
DuloxetineMethyclothiazide may increase the orthostatic hypotensive activities of Duloxetine.
EmpagliflozinThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Methyclothiazide.
EmpagliflozinThe risk or severity of adverse effects can be increased when Empagliflozin is combined with Methyclothiazide.
EnalaprilMethyclothiazide may increase the hypotensive activities of Enalapril.
EnalaprilThe risk or severity of adverse effects can be increased when Enalapril is combined with Methyclothiazide.
EnalaprilatMethyclothiazide may increase the hypotensive activities of Enalaprilat.
EphedraEphedra may increase the hypokalemic activities of Methyclothiazide.
EpinephrineEpinephrine may increase the hypokalemic activities of Methyclothiazide.
EpirizoleThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Epirizole.
EplerenoneThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Eplerenone.
EprosartanThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Eprosartan.
EquileninEquilenin may increase the hypokalemic activities of Methyclothiazide.
EquilinEquilin may increase the hypokalemic activities of Methyclothiazide.
EscitalopramEscitalopram may increase the hyponatremic activities of Methyclothiazide.
EsmololThe risk or severity of adverse effects can be increased when Esmolol is combined with Methyclothiazide.
EstroneEstrone may increase the hypokalemic activities of Methyclothiazide.
Etacrynic acidThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Etacrynic acid.
EtanerceptThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Etanercept.
EthanolEthanol may increase the orthostatic hypotensive activities of Methyclothiazide.
EthopropazineThe serum concentration of Methyclothiazide can be increased when it is combined with Ethopropazine.
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Methyclothiazide.
EtodolacThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Etodolac.
EtofenamateThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Etofenamate.
EtoperidoneEtoperidone may increase the hyponatremic activities of Methyclothiazide.
EtoricoxibThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Etoricoxib.
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Methyclothiazide.
Evening primrose oilThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Evening primrose oil.
ExenatideThe therapeutic efficacy of Exenatide can be decreased when used in combination with Methyclothiazide.
exisulindThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with exisulind.
FelodipineThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Felodipine.
FenbufenThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Fenbufen.
FenfluramineFenfluramine may increase the hyponatremic activities of Methyclothiazide.
FenoprofenThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Fenoprofen.
FenoterolFenoterol may increase the hypokalemic activities of Methyclothiazide.
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Methyclothiazide.
FesoterodineThe serum concentration of Methyclothiazide can be increased when it is combined with Fesoterodine.
FloctafenineThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Floctafenine.
FludrocortisoneFludrocortisone may increase the hypokalemic activities of Methyclothiazide.
FlumethasoneFlumethasone may increase the hypokalemic activities of Methyclothiazide.
FlunisolideFlunisolide may increase the hypokalemic activities of Methyclothiazide.
FlunixinThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Flunixin.
Fluocinolone AcetonideFluocinolone Acetonide may increase the hypokalemic activities of Methyclothiazide.
FluocinonideFluocinonide may increase the hypokalemic activities of Methyclothiazide.
FluocortoloneFluocortolone may increase the hypokalemic activities of Methyclothiazide.
FluorometholoneFluorometholone may increase the hypokalemic activities of Methyclothiazide.
FluoxetineFluoxetine may increase the hyponatremic activities of Methyclothiazide.
FluprednideneFluprednidene may increase the hypokalemic activities of Methyclothiazide.
FluprednisoloneFluprednisolone may increase the hypokalemic activities of Methyclothiazide.
FlurandrenolideFlurandrenolide may increase the hypokalemic activities of Methyclothiazide.
FlurbiprofenThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Flurbiprofen.
Fluticasone furoateFluticasone furoate may increase the hypokalemic activities of Methyclothiazide.
Fluticasone PropionateFluticasone Propionate may increase the hypokalemic activities of Methyclothiazide.
FluvoxamineFluvoxamine may increase the hyponatremic activities of Methyclothiazide.
FormoterolFormoterol may increase the hypokalemic activities of Methyclothiazide.
FosinoprilMethyclothiazide may increase the hypotensive activities of Fosinopril.
FosinoprilThe risk or severity of adverse effects can be increased when Fosinopril is combined with Methyclothiazide.
FurosemideThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Furosemide.
Gallamine TriethiodideThe serum concentration of Methyclothiazide can be increased when it is combined with Gallamine Triethiodide.
GlibornurideThe therapeutic efficacy of Glibornuride can be decreased when used in combination with Methyclothiazide.
GliclazideThe therapeutic efficacy of Gliclazide can be decreased when used in combination with Methyclothiazide.
GlimepirideThe therapeutic efficacy of Glimepiride can be decreased when used in combination with Methyclothiazide.
GlipizideThe therapeutic efficacy of Glipizide can be decreased when used in combination with Methyclothiazide.
GliquidoneThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Methyclothiazide.
GlyburideThe therapeutic efficacy of Glyburide can be decreased when used in combination with Methyclothiazide.
GlycopyrroniumThe serum concentration of Methyclothiazide can be increased when it is combined with Glycopyrronium.
GuanfacineThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Guanfacine.
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Methyclothiazide.
HexamethoniumThe serum concentration of Methyclothiazide can be increased when it is combined with Hexamethonium.
HexobarbitalHexobarbital may increase the orthostatic hypotensive activities of Methyclothiazide.
HMPL-004The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with HMPL-004.
HomatropineThe serum concentration of Methyclothiazide can be increased when it is combined with Homatropine.
HydralazineThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Hydralazine.
HydrochlorothiazideThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Hydrochlorothiazide.
HydrocodoneThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Methyclothiazide.
HydrocortisoneHydrocortisone may increase the hypokalemic activities of Methyclothiazide.
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Methyclothiazide.
HyoscyamineThe serum concentration of Methyclothiazide can be increased when it is combined with Hyoscyamine.
IbuprofenThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Ibuprofen.
IbuproxamThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Ibuproxam.
IcatibantThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Icatibant.
IndacaterolIndacaterol may increase the hypokalemic activities of Methyclothiazide.
IndalpineIndalpine may increase the hyponatremic activities of Methyclothiazide.
IndapamideThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Indapamide.
IndomethacinThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Indomethacin.
IndoprofenThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Indoprofen.
Insulin AspartThe therapeutic efficacy of Insulin Aspart can be decreased when used in combination with Methyclothiazide.
Insulin DetemirThe therapeutic efficacy of Insulin Detemir can be decreased when used in combination with Methyclothiazide.
Insulin GlargineThe therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Methyclothiazide.
Insulin GlulisineThe therapeutic efficacy of Insulin Glulisine can be decreased when used in combination with Methyclothiazide.
Insulin LisproThe therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Methyclothiazide.
Insulin PorkThe therapeutic efficacy of Insulin Pork can be decreased when used in combination with Methyclothiazide.
Ipratropium bromideThe serum concentration of Methyclothiazide can be increased when it is combined with Ipratropium bromide.
IrbesartanThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Irbesartan.
IsoetarineIsoetarine may increase the hypokalemic activities of Methyclothiazide.
IsoprenalineIsoprenaline may increase the hypokalemic activities of Methyclothiazide.
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Isosorbide Dinitrate.
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Isosorbide Mononitrate.
IsoxicamThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Isoxicam.
IsoxsuprineThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Isoxsuprine.
IsradipineThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Isradipine.
IvabradineMethyclothiazide may increase the arrhythmogenic activities of Ivabradine.
KebuzoneThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Kebuzone.
KetobemidoneThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Methyclothiazide.
KetoprofenThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Ketoprofen.
KetorolacThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Ketorolac.
LabetalolThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Labetalol.
LeflunomideThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Leflunomide.
LevobunololThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Levobunolol.
LevodopaMethyclothiazide may increase the orthostatic hypotensive activities of Levodopa.
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Methyclothiazide.
LevomilnacipranLevomilnacipran may increase the hyponatremic activities of Methyclothiazide.
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Methyclothiazide.
LicoriceLicorice may increase the hypokalemic activities of Methyclothiazide.
LinagliptinThe therapeutic efficacy of Linagliptin can be decreased when used in combination with Methyclothiazide.
LiraglutideThe therapeutic efficacy of Liraglutide can be decreased when used in combination with Methyclothiazide.
LisinoprilMethyclothiazide may increase the hypotensive activities of Lisinopril.
LisinoprilThe risk or severity of adverse effects can be increased when Lisinopril is combined with Methyclothiazide.
LithiumMethyclothiazide may decrease the excretion rate of Lithium which could result in a lower serum level and potentially a reduction in efficacy.
LofentanilThe risk or severity of adverse effects can be increased when Lofentanil is combined with Methyclothiazide.
LornoxicamThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Lornoxicam.
LosartanThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Losartan.
LoxoprofenThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Loxoprofen.
Lu AA21004Lu AA21004 may increase the hyponatremic activities of Methyclothiazide.
LumiracoxibThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Lumiracoxib.
Magnesium salicylateThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Magnesium salicylate.
MannitolThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Mannitol.
MasoprocolThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Masoprocol.
MecamylamineThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Mecamylamine.
MecamylamineThe serum concentration of Methyclothiazide can be increased when it is combined with Mecamylamine.
Meclofenamic acidThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Meclofenamic acid.
MedrysoneMedrysone may increase the hypokalemic activities of Methyclothiazide.
Mefenamic acidThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Mefenamic acid.
MelengestrolMelengestrol may increase the hypokalemic activities of Methyclothiazide.
MeloxicamThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Meloxicam.
MesalazineThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Mesalazine.
MetamizoleThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Metamizole.
MetforminThe therapeutic efficacy of Metformin can be decreased when used in combination with Methyclothiazide.
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Methyclothiazide.
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Methyclothiazide.
MethanthelineThe serum concentration of Methyclothiazide can be increased when it is combined with Methantheline.
MethazolamideThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Methazolamide.
MethohexitalMethohexital may increase the orthostatic hypotensive activities of Methyclothiazide.
MethyldopaThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Methyldopa.
MethylphenobarbitalMethylphenobarbital may increase the orthostatic hypotensive activities of Methyclothiazide.
MethylprednisoloneMethylprednisolone may increase the hypokalemic activities of Methyclothiazide.
MetipranololThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Metipranolol.
MetixeneThe serum concentration of Methyclothiazide can be increased when it is combined with Metixene.
MetolazoneThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Metolazone.
MetoprololThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Metoprolol.
MiglitolThe therapeutic efficacy of Miglitol can be decreased when used in combination with Methyclothiazide.
MiglustatThe therapeutic efficacy of Miglustat can be decreased when used in combination with Methyclothiazide.
MilnacipranMilnacipran may increase the hyponatremic activities of Methyclothiazide.
MinoxidilThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Minoxidil.
MitiglinideThe therapeutic efficacy of Mitiglinide can be decreased when used in combination with Methyclothiazide.
MoexiprilMethyclothiazide may increase the hypotensive activities of Moexipril.
MoexiprilThe risk or severity of adverse effects can be increased when Moexipril is combined with Methyclothiazide.
MometasoneMometasone may increase the hypokalemic activities of Methyclothiazide.
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Methyclothiazide.
Mycophenolate mofetilThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Mycophenolate mofetil.
Mycophenolic acidThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Mycophenolic acid.
N-butylscopolammonium bromideThe serum concentration of Methyclothiazide can be increased when it is combined with N-butylscopolammonium bromide.
NabumetoneThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Nabumetone.
NadololThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Nadolol.
NaftifineThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Naftifine.
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Methyclothiazide.
NaproxenThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Naproxen.
NateglinideThe therapeutic efficacy of Nateglinide can be decreased when used in combination with Methyclothiazide.
NCX 4016The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with NCX 4016.
NebivololThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Nebivolol.
NepafenacThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Nepafenac.
NesiritideThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Nesiritide.
NicardipineThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Nicardipine.
NicorandilNicorandil may increase the hypotensive activities of Methyclothiazide.
NifedipineThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Nifedipine.
Niflumic AcidThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Niflumic Acid.
NimesulideThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Nimesulide.
NimodipineThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Nimodipine.
NisoldipineThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Nisoldipine.
NitroglycerinThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Nitroglycerin.
NitroprussideThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Nitroprusside.
NorepinephrineNorepinephrine may increase the hypokalemic activities of Methyclothiazide.
NormethadoneThe risk or severity of adverse effects can be increased when Normethadone is combined with Methyclothiazide.
NVA237The serum concentration of Methyclothiazide can be increased when it is combined with NVA237.
OlanzapineOlanzapine may increase the hyponatremic activities of Methyclothiazide.
OlmesartanThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Olmesartan.
OlodaterolOlodaterol may increase the hypokalemic activities of Methyclothiazide.
OlopatadineThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Olopatadine.
OlsalazineThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Olsalazine.
OmapatrilatMethyclothiazide may increase the hypotensive activities of Omapatrilat.
OpiumThe risk or severity of adverse effects can be increased when Opium is combined with Methyclothiazide.
OrciprenalineOrciprenaline may increase the hypokalemic activities of Methyclothiazide.
OrgoteinThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Orgotein.
OrphenadrineThe serum concentration of Methyclothiazide can be increased when it is combined with Orphenadrine.
OuabainThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Ouabain.
OxaprozinThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Oxaprozin.
OxcarbazepineThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Oxcarbazepine.
OxybutyninThe serum concentration of Methyclothiazide can be increased when it is combined with Oxybutynin.
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Methyclothiazide.
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Methyclothiazide.
OxyphenbutazoneThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Oxyphenbutazone.
OxyphenoniumThe serum concentration of Methyclothiazide can be increased when it is combined with Oxyphenonium.
PancuroniumThe serum concentration of Methyclothiazide can be increased when it is combined with Pancuronium.
PapaverineThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Papaverine.
ParamethasoneParamethasone may increase the hypokalemic activities of Methyclothiazide.
ParecoxibThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Parecoxib.
ParoxetineParoxetine may increase the hyponatremic activities of Methyclothiazide.
PenbutololThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Penbutolol.
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Methyclothiazide.
PentobarbitalPentobarbital may increase the orthostatic hypotensive activities of Methyclothiazide.
PentoliniumThe serum concentration of Methyclothiazide can be increased when it is combined with Pentolinium.
PerindoprilMethyclothiazide may increase the hypotensive activities of Perindopril.
PerindoprilThe risk or severity of adverse effects can be increased when Perindopril is combined with Methyclothiazide.
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Methyclothiazide.
PhenforminThe therapeutic efficacy of Phenformin can be decreased when used in combination with Methyclothiazide.
PhenobarbitalPhenobarbital may increase the orthostatic hypotensive activities of Methyclothiazide.
PhenylbutazoneThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Phenylbutazone.
PhenylpropanolaminePhenylpropanolamine may increase the hypokalemic activities of Methyclothiazide.
PimecrolimusThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Pimecrolimus.
PindololThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Pindolol.
PioglitazoneThe therapeutic efficacy of Pioglitazone can be decreased when used in combination with Methyclothiazide.
PipecuroniumThe serum concentration of Methyclothiazide can be increased when it is combined with Pipecuronium.
PirbuterolPirbuterol may increase the hypokalemic activities of Methyclothiazide.
PirenzepineThe serum concentration of Methyclothiazide can be increased when it is combined with Pirenzepine.
PirfenidoneThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Pirfenidone.
PiroxicamThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Piroxicam.
PramlintideThe therapeutic efficacy of Pramlintide can be decreased when used in combination with Methyclothiazide.
PrazosinThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Prazosin.
PrednicarbatePrednicarbate may increase the hypokalemic activities of Methyclothiazide.
PrednisolonePrednisolone may increase the hypokalemic activities of Methyclothiazide.
PrednisonePrednisone may increase the hypokalemic activities of Methyclothiazide.
PregnenolonePregnenolone may increase the hypokalemic activities of Methyclothiazide.
PrimidonePrimidone may increase the orthostatic hypotensive activities of Methyclothiazide.
ProcaterolProcaterol may increase the hypokalemic activities of Methyclothiazide.
ProcyclidineThe serum concentration of Methyclothiazide can be increased when it is combined with Procyclidine.
PropacetamolThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Propacetamol.
PropanthelineThe serum concentration of Methyclothiazide can be increased when it is combined with Propantheline.
PropranololThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Propranolol.
PTC299The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with PTC299.
QuetiapineThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Quetiapine.
QuinaprilMethyclothiazide may increase the hypotensive activities of Quinapril.
QuinaprilThe risk or severity of adverse effects can be increased when Quinapril is combined with Methyclothiazide.
QuinidineThe serum concentration of Methyclothiazide can be increased when it is combined with Quinidine.
RamiprilMethyclothiazide may increase the hypotensive activities of Ramipril.
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Methyclothiazide.
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Methyclothiazide.
RepaglinideThe therapeutic efficacy of Repaglinide can be decreased when used in combination with Methyclothiazide.
RescinnamineMethyclothiazide may increase the hypotensive activities of Rescinnamine.
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Methyclothiazide.
ResveratrolThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Resveratrol.
RimexoloneRimexolone may increase the hypokalemic activities of Methyclothiazide.
RiociguatThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Riociguat.
RisperidoneMethyclothiazide may increase the hypotensive activities of Risperidone.
RitodrineRitodrine may increase the hypokalemic activities of Methyclothiazide.
RofecoxibThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Rofecoxib.
RosiglitazoneThe therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Methyclothiazide.
SalbutamolSalbutamol may increase the hypokalemic activities of Methyclothiazide.
SalicylamideThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Salicylamide.
Salicylic acidThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Salicylic acid.
SalmeterolSalmeterol may increase the hypokalemic activities of Methyclothiazide.
SalsalateThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Salsalate.
SaxagliptinThe therapeutic efficacy of Saxagliptin can be decreased when used in combination with Methyclothiazide.
ScopolamineThe serum concentration of Methyclothiazide can be increased when it is combined with Scopolamine.
Scopolamine butylbromideThe serum concentration of Methyclothiazide can be increased when it is combined with Scopolamine butylbromide.
SecobarbitalSecobarbital may increase the orthostatic hypotensive activities of Methyclothiazide.
SeratrodastThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Seratrodast.
SertralineSertraline may increase the hyponatremic activities of Methyclothiazide.
SitagliptinThe therapeutic efficacy of Sitagliptin can be decreased when used in combination with Methyclothiazide.
SolifenacinThe serum concentration of Methyclothiazide can be increased when it is combined with Solifenacin.
SotalolThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Sotalol.
SpiraprilMethyclothiazide may increase the hypotensive activities of Spirapril.
SpironolactoneThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Spironolactone.
SRT501The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with SRT501.
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Methyclothiazide.
SulfasalazineThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Sulfasalazine.
SulindacThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Sulindac.
SulodexideThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Methyclothiazide.
SulpirideThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Sulpiride.
SuprofenThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Suprofen.
TapentadolThe risk or severity of adverse effects can be increased when Tapentadol is combined with Methyclothiazide.
TelmisartanThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Telmisartan.
TemocaprilMethyclothiazide may increase the hypotensive activities of Temocapril.
TenoxicamThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Tenoxicam.
TepoxalinThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Tepoxalin.
TerazosinThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Terazosin.
TerbutalineTerbutaline may increase the hypokalemic activities of Methyclothiazide.
TeriflunomideThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Teriflunomide.
ThiamylalThiamylal may increase the orthostatic hypotensive activities of Methyclothiazide.
ThiopentalThiopental may increase the orthostatic hypotensive activities of Methyclothiazide.
Tiaprofenic acidThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Tiaprofenic acid.
TimololThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Timolol.
TiotropiumThe serum concentration of Methyclothiazide can be increased when it is combined with Tiotropium.
TixocortolTixocortol may increase the hypokalemic activities of Methyclothiazide.
TizanidineThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Tizanidine.
TolazamideThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Methyclothiazide.
TolbutamideThe therapeutic efficacy of Tolbutamide can be decreased when used in combination with Methyclothiazide.
Tolfenamic AcidThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Tolfenamic Acid.
TolmetinThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Tolmetin.
TolterodineThe serum concentration of Methyclothiazide can be increased when it is combined with Tolterodine.
TopiramateMethyclothiazide may increase the hypokalemic activities of Topiramate.
TorasemideThe risk or severity of adverse effects can be increased when Torasemide is combined with Methyclothiazide.
ToremifeneMethyclothiazide may increase the hypercalcemic activities of Toremifene.
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Methyclothiazide.
TrandolaprilMethyclothiazide may increase the hypotensive activities of Trandolapril.
TrandolaprilThe risk or severity of adverse effects can be increased when Trandolapril is combined with Methyclothiazide.
TranilastThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Tranilast.
TrazodoneTrazodone may increase the hyponatremic activities of Methyclothiazide.
TriamcinoloneTriamcinolone may increase the hypokalemic activities of Methyclothiazide.
TriamtereneThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Triamterene.
TrihexyphenidylThe serum concentration of Methyclothiazide can be increased when it is combined with Trihexyphenidyl.
TrimethaphanThe serum concentration of Methyclothiazide can be increased when it is combined with Trimethaphan.
Trisalicylate-cholineThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Trisalicylate-choline.
TroglitazoneThe therapeutic efficacy of Troglitazone can be decreased when used in combination with Methyclothiazide.
TropicamideThe serum concentration of Methyclothiazide can be increased when it is combined with Tropicamide.
TrospiumThe serum concentration of Methyclothiazide can be increased when it is combined with Trospium.
TubocurarineThe serum concentration of Methyclothiazide can be increased when it is combined with Tubocurarine.
UmeclidiniumThe serum concentration of Methyclothiazide can be increased when it is combined with Umeclidinium.
ValdecoxibThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Valdecoxib.
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Methyclothiazide.
VecuroniumThe serum concentration of Methyclothiazide can be increased when it is combined with Vecuronium.
VerapamilThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Verapamil.
VilanterolVilanterol may increase the hypokalemic activities of Methyclothiazide.
VilazodoneVilazodone may increase the hyponatremic activities of Methyclothiazide.
VildagliptinThe therapeutic efficacy of Vildagliptin can be decreased when used in combination with Methyclothiazide.
VogliboseThe therapeutic efficacy of Voglibose can be decreased when used in combination with Methyclothiazide.
VortioxetineVortioxetine may increase the hyponatremic activities of Methyclothiazide.
ZaltoprofenThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Zaltoprofen.
ZileutonThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Zileuton.
ZimelidineZimelidine may increase the hyponatremic activities of Methyclothiazide.
ZomepiracThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Zomepirac.
Food InteractionsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Sodium:potassium:chloride symporter activity
Specific Function:
Electrically silent transporter system. Mediates sodium and chloride reabsorption. Plays a vital role in the regulation of ionic balance and cell volume.
Gene Name:
SLC12A1
Uniprot ID:
Q13621
Molecular Weight:
121449.13 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Zinc ion binding
Specific Function:
Reversible hydration of carbon dioxide. Can hydrates cyanamide to urea.
Gene Name:
CA1
Uniprot ID:
P00915
Molecular Weight:
28870.0 Da
References
  1. Puscas I, Coltau M, Baican M, Domuta G, Hecht A: Vasodilatory effect of diuretics is dependent on inhibition of vascular smooth muscle carbonic anhydrase by a direct mechanism of action. Drugs Exp Clin Res. 1999;25(6):271-9. [PubMed:10713865 ]
  2. Couloigner V, Loiseau A, Sterkers O, Amiel C, Ferrary E: Effect of locally applied drugs on the endolymphatic sac potential. Laryngoscope. 1998 Apr;108(4 Pt 1):592-8. [PubMed:9546276 ]
  3. Temperini C, Cecchi A, Scozzafava A, Supuran CT: Carbonic anhydrase inhibitors. Comparison of chlorthalidone, indapamide, trichloromethiazide, and furosemide X-ray crystal structures in adducts with isozyme II, when several water molecules make the difference. Bioorg Med Chem. 2009 Feb 1;17(3):1214-21. doi: 10.1016/j.bmc.2008.12.023. Epub 2008 Dec 24. [PubMed:19119014 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Zinc ion binding
Specific Function:
Essential for bone resorption and osteoclast differentiation (By similarity). Reversible hydration of carbon dioxide. Can hydrate cyanamide to urea. Involved in the regulation of fluid secretion into the anterior chamber of the eye. Contributes to intracellular pH regulation in the duodenal upper villous epithelium during proton-coupled peptide absorption. Stimulates the chloride-bicarbonate ex...
Gene Name:
CA2
Uniprot ID:
P00918
Molecular Weight:
29245.895 Da
References
  1. Meyerson LR, Nesta D: [3H]acetazolamide binding to carbonic anhydrase in normal and transformed cells. Biochem Pharmacol. 1991 Mar 15-Apr 1;41(6-7):995-1000. [PubMed:1901209 ]
  2. Schaeffer P, Vigne P, Frelin C, Lazdunski M: Identification and pharmacological properties of binding sites for the atypical thiazide diuretic, indapamide. Eur J Pharmacol. 1990 Jul 17;182(3):503-8. [PubMed:2226620 ]
  3. Temperini C, Cecchi A, Scozzafava A, Supuran CT: Carbonic anhydrase inhibitors. Comparison of chlorthalidone, indapamide, trichloromethiazide, and furosemide X-ray crystal structures in adducts with isozyme II, when several water molecules make the difference. Bioorg Med Chem. 2009 Feb 1;17(3):1214-21. doi: 10.1016/j.bmc.2008.12.023. Epub 2008 Dec 24. [PubMed:19119014 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Zinc ion binding
Specific Function:
Reversible hydration of carbon dioxide. May stimulate the sodium/bicarbonate transporter activity of SLC4A4 that acts in pH homeostasis. It is essential for acid overload removal from the retina and retina epithelium, and acid release in the choriocapillaris in the choroid.
Gene Name:
CA4
Uniprot ID:
P22748
Molecular Weight:
35032.075 Da
References
  1. Puscas I, Coltau M, Baican M, Domuta G, Hecht A: Vasodilatory effect of diuretics is dependent on inhibition of vascular smooth muscle carbonic anhydrase by a direct mechanism of action. Drugs Exp Clin Res. 1999;25(6):271-9. [PubMed:10713865 ]
  2. Temperini C, Cecchi A, Scozzafava A, Supuran CT: Carbonic anhydrase inhibitors. Comparison of chlorthalidone, indapamide, trichloromethiazide, and furosemide X-ray crystal structures in adducts with isozyme II, when several water molecules make the difference. Bioorg Med Chem. 2009 Feb 1;17(3):1214-21. doi: 10.1016/j.bmc.2008.12.023. Epub 2008 Dec 24. [PubMed:19119014 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23